# Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

> **NCT00890656** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 90 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Decadron
- **DRUG:** G-CSF
- **DRUG:** Methotrexate (MTX)
- **DRUG:** Ara-C
- **DRUG:** Pegaspargase

## Key facts

- **NCT ID:** NCT00890656
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890656, "Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00890656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*